Stock Analysis on Net
Stock Analysis on Net

Elevance Health Inc. (NYSE:ELV)

$24.99

Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Paying user area

Try for free

Elevance Health Inc. pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Elevance Health Inc., consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in millions

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Medical claims payable
Other policyholder liabilities
Unearned income
Accounts payable and accrued expenses
Short-term borrowings
Current portion of long-term debt
Other current liabilities
Liabilities held for sale
Current liabilities
Long-term debt, less current portion
Reserves for future policy benefits
Deferred tax liabilities, net
Other noncurrent liabilities
Noncurrent liabilities
Total liabilities
Preferred stock, without par value; shares issued and outstanding: none
Common stock, par value $0.01
Additional paid-in capital
Retained earnings
Accumulated other comprehensive income (loss)
Shareholders’ equity
Noncontrolling interests
Total equity
Total liabilities and equity

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

Medical Claims Payable
There is a generally upward trend in medical claims payable from March 2020 to June 2025, increasing from 9,902 million USD to 17,155 million USD, with some fluctuations noted particularly in the second half of 2024.
Other Policyholder Liabilities
Other policyholder liabilities peaked around late 2021 and early 2022 but overall show a declining trend from the high of 5,521 million USD at the end of 2021 to 3,540 million USD by mid-2025.
Unearned Income
Unearned income presents volatility with sharp spikes notably in September 2022 and June 2023, reaching upwards of 4,458 million USD, contrasting with lower values in other quarters. It suggests episodic increases followed by reductions.
Accounts Payable and Accrued Expenses
This item exhibits gradual growth over the period, rising from about 5,058 million USD in early 2020 to 7,278 million USD by mid-2025, although some quarters saw minor decreases.
Short-term Borrowings
Short-term borrowings display inconsistent patterns with some missing data and sporadic fluctuations, generally maintaining relatively low values compared to other liabilities, with a notable peak around mid-2024.
Current Portion of Long-term Debt
This liability fluctuated significantly, with a dramatic decline at the end of 2020 followed by periods of increase and decrease, peaking at 2,900 million USD in mid-2024 and then decreasing again by mid-2025.
Other Current Liabilities
Other current liabilities generally increased from 5,202 million USD in March 2020 to over 12,000 million USD by mid-2025, with some intermittent decreases, indicating growth in current obligations.
Liabilities Held for Sale
Data for liabilities held for sale is mostly absent until early 2025, when small amounts around 150-165 million USD are recorded, suggesting new or discontinued liabilities appearing near that period.
Current Liabilities
Current liabilities increased steadily from 27,039 million USD in March 2020 to a peak near 44,334 million USD in late 2024, with slight declines afterwards indicating a peak in short-term obligations.
Long-Term Debt, Less Current Portion
Long-term debt values fluctuate but overall trend downward from 22,534 million USD in March 2021 to around 28,178 million USD by mid-2025, reflecting borrowing and repayments dynamics.
Reserves for Future Policy Benefits
These reserves remain relatively stable but decreased significantly from 802 million USD toward the end of 2021 to 163 million USD by mid-2025, possibly indicating changing policy liabilities or reserve practices.
Deferred Tax Liabilities, Net
Deferred tax liabilities fluctuate moderately with no persistent trend, oscillating between about 1,779 million USD and 2,629 million USD throughout the period.
Other Noncurrent Liabilities
Other noncurrent liabilities show steady growth until late 2023, after which there is a sharp increase starting in early 2024, reaching nearly 4,000 million USD by mid-2025.
Noncurrent Liabilities
Noncurrent liabilities overall increased from approximately 23,667 million USD in early 2020 to a peak above 34,000 million USD by late 2024, indicative of rising long-term financial obligations.
Total Liabilities
Total liabilities rose steadily from 50,706 million USD in March 2020 to 78,087 million USD by mid-2025, reflecting ongoing growth in both current and noncurrent liabilities.
Common Stock
Common stock remained stable at a nominal value of 2-3 million USD, indicating no significant changes in par value or shares issued during the period.
Additional Paid-in Capital
This component declined slightly from over 9,300 million USD in early 2020 to under 8,700 million USD by early 2023 but showed modest recovery, stabilizing around 8,900 million USD toward mid-2025.
Retained Earnings
Retained earnings exhibit consistent growth from 23,360 million USD in early 2020 to approximately 35,549 million USD by mid-2025, signaling accumulation of earnings over time.
Accumulated Other Comprehensive Income (Loss)
This item shows persistent negative balances with considerable volatility, with significant worsening around 2021 and some moderate improvement toward mid-2025 but remaining a liability overall.
Shareholders’ Equity
Shareholders' equity increased steadily from 31,693 million USD at the beginning of 2020 to 43,722 million USD by mid-2025, reflecting retained earnings growth outpacing accumulated losses in other comprehensive income.
Noncontrolling Interests
Noncontrolling interests remain modest but trend upwards from absence in early data to around 129 million USD by mid-2025, indicating small but growing external ownership stakes.
Total Equity
Total equity followed the trajectory of shareholders' equity, rising from approximately 31,693 million USD to over 43,851 million USD, demonstrating strengthening equity base despite some fluctuations.
Total Liabilities and Equity
The total of liabilities and equity increased steadily from approximately 82,399 million USD at the start of 2020 to nearly 122,000 million USD by mid-2025, consistent with growth in both liabilities and equity.